

# PEOPLE



Yumanity Therapeutics (Cambridge, MA, USA) has named **Paulash Mohsen** (left) chief business officer. Mohsen has over 18 years of operational, commercial and business development experience in the biotech and pharma industries. He joins Yumanity from Cubist Pharmaceuticals, where he most recently served as country manager for Canada. Previously, he was vice president, strategy and business operations for Optimer Pharmaceuticals, which was acquired by Cubist.

“Paulash has extensive experience in both larger pharmaceutical companies and rapidly growing biotech companies across a variety of key functions,” said Tony Coles, chairman and CEO of Yumanity. “As a result, he brings a unique blend of strategic, operational, commercial and corporate development expertise that is well suited to our long-term plans.”

Amicus Therapeutics (Cranbury, NJ, USA) has announced the appointment of **David Allsop** as senior vice president, international. He most recently served as Biogen’s senior vice president, Europe and Canada.

**Stéphane Boissel** has been appointed CEO of immunotherapy developer TxCell (Valbonne, France), succeeding **Damian Marron**, who resigned from the company to pursue other interests. Previously, Boissel served as CEO of Genclis and executive vice president and CFO of Transgene. In addition, TxCell has announced the promotion of **Miguel Forte** from senior vice president, clinical and regulatory, to COO.

Allena Pharmaceuticals (Newton, MA, USA) has named **Louis Brenner** COO. He joins the company from Idera Pharmaceuticals, where he served as senior vice president and chief medical officer. Allena cofounder and former COO **Robert Gallotto** will remain as a strategic adviser to the company as he transitions to focus more exclusively on his role as president of Alcresta.

Privately held Chiasma (Newton, MA, USA) has named **Mark J. Fitzpatrick** CFO. He joins the company from Aegerion Pharmaceuticals, where he served as CFO since 2011. Prior to Aegerion, Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics and vice president and CFO, treasurer and assistant secretary at RenaMed Biologics.

Gene therapy company Voyager Therapeutics (Cambridge, MA, USA) has announced the appointment of **Jeff Goater**, former vice president of business development, to senior vice president, finance and business development.

Goater had served as vice president of business development since Voyager’s launch in 2014. Previously, he was a managing director at Evercore Partners, focused on strategic advisory in the life sciences sector.



Kala Pharmaceuticals (Waltham, MA, USA) has appointed **Mark Iwicki** (left) executive chairman and member of its board of directors. Iwicki has 25 years of pharma industry experience, most recently

as president and CEO of Civitas Therapeutics, which was acquired by Acorda Therapeutics. Prior to joining Civitas, he served as CEO of Blend Therapeutics and as CEO of Sunovion Pharmaceuticals, which was created after the acquisition of Sepracor Pharmaceuticals by Sumitomo Dainippon Pharma.

**Jyrki Mattila** has been appointed to the newly created position of executive vice president and chief business officer at specialty pharma company Lipocine (Salt Lake City). Mattila brings over 25 years of business development and management experience, most recently at iCeutica Operations, where he served as chief business officer. Prior to iCeutica, he was president and CEO of LZ Therapeutics.

Otonomy (San Diego) has announced the appointments of **George J. Morrow** to the board of directors and **Eric Loumeau** as general counsel and chief compliance officer. Morrow was most recently executive vice president, global

commercial operations, at Amgen. He currently serves on the board of directors of Vical and Align Technology. Loumeau was vice president of legal affairs at The Medicines Company, which he joined following the company’s acquisition of Rempex Pharmaceuticals. In addition, Otonomy also announced that **Brian Dovey**, partner at Domain Associates, and **John McKearn**, managing director of RiverVest Venture Partners, will step down from the board of directors following Otonomy’s annual meeting of stockholders this month.

Cell therapy developer TissueGene (Rockville, MD, USA) has appointed **Robert A. Newman** to the position of COO. Newman was most recently senior vice president, manufacturing, program management & clinical operations at Ziopharm Oncology.

**Riccardo Pigiucci** has been appointed to the Affymetrix (Santa Clara, CA, USA) board of directors. He has served as the managing partner of Aldwych Associates, a management and technology consulting partnership, since 2006.

**David R. Parkinson** has been appointed to the board of directors of Tocagen (San Diego). He is presently a venture partner at New Enterprise Associates and was previously vice president of oncology development at Amgen, vice president of global clinical oncology development at Novartis and senior vice president at Biogen Idec. He also currently serves on the board of directors of Threshold Pharmaceuticals and Cerulean Pharma.

Cell therapy company Apceth (Munich) has announced the appointment of **Ulrike Verzetnitsch** as chief technical officer. She joins the company from Takeda, where she was head of the production unit in Singen, Germany. Previously, she held the position of director of production with Baxter.

**Rolf G. Werner** has been appointed chairman of the scientific board of AMP Biosimilars (Hamburg). Werner is a professor of industrial biotech and an honorary senator at the Eberhard Karls University Tübingen. He also has more than 35 years of industry experience in various leadership positions at Boehringer Ingelheim, including head of global biopharmaceuticals.